Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03953300 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics

Study acronym: CHINOOK
StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 75 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria shortened, about 10 words Secondary endpoints: details revised at 10 of 35 entries Show 1 more changeShow less
    • Secondary endpoints: details revised at 10 of 35 entries
  2. 7 versions Re-verified since Mar 10, 2026, no change to tracked fieldsv68-v74
  3. Primary and study completion dates: Sep 9, 2026 to Oct 19, 2026v67
  4. Re-verified, no change to tracked fieldsv66
  5. Enrollment target: 74 to 75v65
Show 39 earlier versionsHide 39 earlier versions
  1. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 81 to confirmed 74 · Study sites: 53 to 35 · Start date: Oct 17, 2019 to Oct 8, 2019v64 Show 3 more changesShow less
    • Enrollment target: estimated 81 to confirmed 74
    • Study sites: 53 to 35
    • Start date: Oct 17, 2019 to Oct 8, 2019
  2. 2 versions Re-verified since Jun 13, 2025, no change to tracked fieldsv62-v63
  3. Site details revised at 1 of 53 sitesv61
  4. Site details revised at 2 of 53 sitesv60
  5. Re-verified, no change to tracked fieldsv59
  6. Site details revised at 8 of 53 sitesv58
  7. Site details revised at 5 of 53 sitesv57
  8. Site details revised at 1 of 53 sitesv56
  9. Site details revised at 25 of 53 sitesv55
  10. Study sites: 45 to 53v54
  11. Site details revised at 3 of 45 sitesv53
  12. Site details revised at 1 of 45 sitesv52
  13. Site details revised at 2 of 45 sitesv51
  14. Study sites: 44 to 45v50
  15. Study sites: 41 to 44v49
  16. Study sites: 38 to 41v48
  17. Study sites: 37 to 38v47
  18. Re-verified, no change to tracked fieldsv46
  19. Study sites: 36 to 37v45
  20. Site details revised at 1 of 36 sitesv44
  21. Study sites: 35 to 36v43
  22. Study sites: 36 to 35 Eligibility criteria expanded, about 22 words · Secondary endpoints: 34 to 35v42 Show 2 more changesShow less
    • Eligibility criteria expanded, about 22 words
    • Secondary endpoints: 34 to 35

    See this version in full on ClinicalTrials.gov ↗

  23. 3 versions Re-verified since Jun 12, 2023, no change to tracked fieldsv39-v41
  24. Primary and study completion dates: Sep 30, 2025 to Sep 9, 2026v38
  25. Site details revised at 3 of 36 sitesv37
  26. Site details revised at 2 of 36 sitesv36
  27. Site details revised at 3 of 36 sitesv35
  28. Site details revised at 5 of 36 sitesv34
  29. Site details revised at 1 of 36 sitesv33
  30. Site details revised at 1 of 36 sitesv32
  31. Site details revised at 2 of 36 sitesv31
  32. Re-verified, no change to tracked fieldsv30
  33. Site details revised at 2 of 36 sitesv29
  34. 2 versions Re-verified since Jul 29, 2022, no change to tracked fieldsv27-v28
  35. Primary and study completion dates: Sep 29, 2023 to Sep 30, 2025 Study sites: 37 to 36 · Start date: Oct 8, 2019 to Oct 17, 2019v26 Show 2 more changesShow less
    • Study sites: 37 to 36
    • Start date: Oct 8, 2019 to Oct 17, 2019
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AstraZeneca
727 trials monitored
See 61 trials at risk
Asthma
927 trials monitored
See 32 trials at risk
The purpose of the study is to evaluate effect of benralizumab on structural and lung function changes in severe eosinophilic asthmatics. Changes will be assessed over 48 week treatment period in patients with persistent symptoms despite standard therapy of inhaled corticosteroids (ICS) plus long acting B2-agonist (LABA) with or without additional controller medication. Patients who complete treatment will enter 4 weeks follow-up period.
Trial Details
NCT Number NCT03953300
Lead Sponsor AstraZeneca
Conditions Asthma
Enrollment 75 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov